Phase 3 readouts expected in 2029

Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2029, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.

Summary

434 studies (374 Phase 3, 60 Phase 2/3) across 331 drugs.

January 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-01 (month only)Pembrolizumab, pemetrexedMerck & Co., Eli LillyMetastatic Non-squamous Lung CancerPhase 3NCT05692999
2029-01 (month only)TaletrectinibEisai, Innovent Biologics, Nippon KayakuNon-Small Cell Lung CancerPhase 3NCT06564324
2029-01 (month only)Cetuximab, TretinoinEli Lilly, Merck KGaA, Cheplapharm Arzneimittel GmbHOropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck TumorPhase 3NCT06706401
2029-01 (month only)Pumitamig, pemetrexedBioNTech, Bristol-Myers Squibb, Eli LillyNon-Small Cell Lung CancerPhase 2/3NCT06712316
2029-01 (month only)MethylprednisolonePfizerAcute Ischemic StrokePhase 3NCT06870448
2029-01 (month only)Deramciclane, DeraphanExciva GmbHAlzheimer's DiseasePhase 2/3NCT07284472
2029-01 (month only)dupilumabRegeneron Pharmaceuticals, SanofiAsthmaPhase 3NCT07309614
2029-01 (month only)Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd., RochePancreatic Ductal AdenocarcinomaPhase 3NCT07803783
2029-01 (month only)SuzetrigineVertex PharmaceuticalsTotal Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\), Total Knee Replacement, Total Knee Replacement Surgery, Total Knee Replacements, Total Knee Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled TrialsPhase 3NCT07864896
2029-01 (month only)Zopapogene imadenovecPrecigen, IncRecurrent Respiratory PapillomatosisPhase 3NCT07901738
2029-01-01deucravacitinibBristol-Myers SquibbPsoriasisPhase 3NCT04772079
2029-01-01Nab-paclitaxel, GemcitabineBristol-Myers Squibb, Eli LillyPancreatic Ductal Adenocarcinoma, Pancreatic CancerPhase 3NCT06897644
2029-01-01Bortezomib, AcalabrutinibJanssen, Takeda Pharmaceutical Company, AstraZenecaHematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA AntibodiesPhase 3NCT07635511
2029-01-01Nab-paclitaxel, CamrelizumabBristol-Myers Squibb, Elevar Therapeutics, Inc., Jiangsu Hengrui PharmaceuticalsHead and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck CancerPhase 3NCT07948317
2029-01-02RilvegostomigAstraZeneca, COMPUGEN LTDBiliary Tract CancerPhase 3NCT06109779
2029-01-02Letrozole, AtirmociclibNovartis, PfizerHR+/HER2- Metastatic Breast CancerPhase 3NCT06760637
2029-01-04Durvalumab, TarlatamabAstraZeneca, AmgenSmall Cell Lung CancerPhase 3NCT07005128
2029-01-08Sintilimab, FruquintinibInnovent Biologics, HUTCHMED, Takeda Pharmaceutical CompanyEndometrial CancerPhase 3NCT06584032
2029-01-09Rimegepant (Nurtec ODT)Eisai, PfizerMigrainePhase 3NCT04649242
2029-01-11zenagamtideNovo NordiskObesityPhase 3NCT07668401
2029-01-11Daratumumab, Bortezomib, Lenalidomide, Isatuximab, AZD0120, DexamethasoneJohnson & Johnson, Janssen, Takeda Pharmaceutical CompanyMultiple MyelomaPhase 3NCT07764978
2029-01-12Nab-paclitaxel, Pembrolizumab, Sacituzumab TirumotecanBristol-Myers Squibb, Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Non-Small Cell Lung CancerPhase 3NCT06422143
2029-01-15DapagliflozinAstraZeneca, Ono PharmaceuticalHeart Failure, Chronic Kidney DiseasePhase 3NCT07025629
2029-01-17FazirsiranArrowhead Pharmaceuticals, Takeda Pharmaceutical CompanyAlpha-1 Antitrypsin DeficiencyPhase 3NCT05677971
2029-01-19Pembrolizumab, Rilvegostomig, Trastuzumab DeruxtecanMerck & Co., AstraZeneca, COMPUGEN LTDEndometrial CancerPhase 3NCT06989112
2029-01-24HS-10380Hansoh Pharmaceutical GroupSchizophreniaPhase 3NCT07911787
2029-01-25F182112Shandong New Time Pharmaceutical Co., Ltd.Multiple MyelomaPhase 3NCT07579234
2029-01-26Izalontamab brengitecanBristol-Myers Squibb, Sichuan Baili PharmaceuticalUrothelial CarcinomaPhase 2/3NCT07106762
2029-01-26AnifrolumabAstraZeneca, MedImmune LLCSystemic Lupus ErythematosusPhase 3NCT07430306
2029-01-28MosliciguatBayer, Pulmovant, Roivant Sciences Ltd.Pulmonary Hypertension Associated with Interstitial Lung DiseasePhase 3NCT07816185
2029-01-29BelumosudilKadmon Corporation, Meiji Seika Pharma, SanofiLung Transplant RejectionPhase 3NCT06082037
2029-01-29Balstilimab, Botensilimab, DocetaxelAgenus Inc., Zydus Lifesciences, SanofiResectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid TumorsPhase 2/3NCT06279130
2029-01-29Datopotamab DeruxtecanAstraZeneca, Daiichi SankyoNon-Small Cell Lung CancerPhase 3NCT07291037
2029-01-31GemcitabineEli LillyEBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7Phase 2/3NCT02135042
2029-01-31AvelumabMerck KGaAMerkel Cell CarcinomaPhase 3NCT03271372
2029-01-31EtelcalcetideAmgen, Ono PharmaceuticalChronic Kidney Disease, Secondary HyperparathyroidismPhase 3NCT03633708
2029-01-31MethylprednisolonePfizerCardiac ArrestPhase 3NCT05139849
2029-01-31Carfilzomib, Daratumumab, Pomalidomide, Lenalidomide, DexamethasoneAmgen, Ono Pharmaceutical, Johnson & JohnsonMultiple MyelomaPhase 3NCT05438043
2029-01-31onabotulinumtoxinAAbbVieMigrainePhase 3NCT07040813
2029-01-31Toripalimab, CapecitabineCoherus BioSciences, Inc., Shanghai Junshi Bioscience, Cheplapharm Arzneimittel GmbHGastric AdenocarcinomaPhase 3NCT07584135
2029-01-31tocilizumabChugai Pharma, RocheAcute Ischemic StrokePhase 2/3NCT07870681
2029-01-31ModafinilApotex Inc.Mitochondrial DiseasePhase 3NCT07887412

February 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-02 (month only)risankizumabAbbVie, Boehringer IngelheimCrohn's DiseasePhase 3NCT03105102
2029-02 (month only)AmbroxolAgyany Pharma LtdParkinson's DiseasePhase 3NCT05778617
2029-02 (month only)AcalabrutinibAstraZenecaDiffuse Large B-Cell LymphomaPhase 3NCT05820841
2029-02 (month only)Pegozafermin89bio, RocheMASH / NASHPhase 3NCT06318169
2029-02 (month only)retatrutideEli LillyObesity, Chronic Kidney Disease, Atherosclerotic Cardiovascular DiseasePhase 3NCT06383390
2029-02 (month only)Pembrolizumab, LNS8801Merck & Co., Linnaeus Therapeutics, Inc.MelanomaPhase 2/3NCT06624644
2029-02 (month only)VebreltinibApollomics Inc., Avistone BiotechnologyNon-Small Cell Lung CancerPhase 3NCT06930794
2029-02 (month only)upadacitinibAbbVieAlopecia AreataPhase 3NCT07023302
2029-02 (month only)RemlifanserinAcadia PharmaceuticalsLewy Body Dementia PsychosisPhase 3NCT07095465
2029-02 (month only)131I-apamistamabActinium PharmaceuticalsAcute Myeloid LeukemiaPhase 2/3NCT07157514
2029-02 (month only)FurmonertinibAllist Pharmaceuticals, ArriVent BioPharmaNon-Small Cell Lung CancerPhase 3NCT07185997
2029-02 (month only)MLC901Moleac Pte LtdAlzheimer's DiseasePhase 3NCT07191028
2029-02 (month only)Ribociclib, LetrozoleNovartisHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07340658
2029-02-01Atezolizumab, BevacizumabChugai Pharma, RocheHepatocellular CarcinomaPhase 3NCT04712643
2029-02-01TarlatamabAmgenNeuroendocrine CarcinomaPhase 3NCT06937905
2029-02-01LenalidomideBristol-Myers Squibb, Celgene CorporationCutaneous Lupus Erythematosus (CLE)Phase 3NCT06965244
2029-02-01Islatravir, UlonivirineMerck & Co.HIVPhase 2/3NCT07266831
2029-02-01Gilteritinib, Venetoclax, AzacitidineAstellas Pharma, AbbVie, RocheAcute Myeloid LeukemiaPhase 3NCT07407140
2029-02-04AndecaliximabAshibio IncFibrodysplasia Ossificans ProgressivaPhase 2/3NCT06508021
2029-02-04VicadrostatBoehringer IngelheimHeart FailurePhase 3NCT06935370
2029-02-05zenagamtideNovo NordiskObesityPhase 3NCT07822061
2029-02-06FenfluramineNippon Shinyaku, UCBRett SyndromePhase 3NCT07503444
2029-02-07DexamethasoneSevere BurnsPhase 3NCT06968559
2029-02-14Bortezomib, Lenalidomide, Ciltacabtagene autoleucel, DexamethasoneJanssen, Takeda Pharmaceutical Company, Bristol-Myers SquibbMultiple MyelomaPhase 3NCT04923893
2029-02-14AmbrisentanGilead Sciences, GlaxoSmithKlinePulmonary Arterial HypertensionPhase 3NCT07245680
2029-02-14DR10624Zhejiang Doer BiologicsSevere HypertriglyceridemiaPhase 3NCT07693777
2029-02-15FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsAsthmaPhase 3NCT07780643
2029-02-20CapecitabineCheplapharm Arzneimittel GmbHColorectal CancerPhase 3NCT05797077
2029-02-21BerobenatidePfizerObesityPhase 3NCT07794774
2029-02-26remibrutinibNovartisChronic Pruritus of Unknown OriginPhase 3NCT07811869
2029-02-27PF-08634404Pfizer, Shenyang Sunshine PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT07222566
2029-02-27ObinutuzumabRocheLupus NephritisPhase 3NCT07767188
2029-02-28PalbociclibPfizerHPV-unrelated Head and Neck Squamous Cell CarcinomaPhase 3NCT04966481
2029-02-28Quetiapine (Seroquel)Cheplapharm Arzneimittel GmbH, Luye Pharma GroupPsychiatric Disorders, InsomniaPhase 2/3NCT06062953
2029-02-28Ribociclib, CamizestrantNovartis, AstraZenecaHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07647328

March 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-03 (month only)VenetoclaxAbbVie, RocheAcute Myeloid LeukemiaPhase 3NCT04628026
2029-03 (month only)AficamtenBayer, Cytokinetics, SanofiHypertrophic CardiomyopathyPhase 2/3NCT04848506
2029-03 (month only)LepodisiranDicerna Pharmaceuticals, Inc., Eli LillyAtherosclerotic Cardiovascular DiseasePhase 3NCT06292013
2029-03 (month only)PlozasiranArrowhead Pharmaceuticals, SanofiSevere Hypertriglyceridemia, HypertriglyceridemiaPhase 3NCT06880770
2029-03 (month only)CemiplimabRegeneron PharmaceuticalsNon-Small Cell Lung CancerPhase 3NCT06931717
2029-03 (month only)Furmonertinib, pemetrexedAllist Pharmaceuticals, ArriVent BioPharma, Eli LillyNon-Small Cell Lung CancerPhase 3NCT06970639
2029-03 (month only)LevosimendanOrion Corporation, Tenax TherapeuticsPulmonary Hypertension Associated With HFpEFPhase 3NCT07436689
2029-03 (month only)Velinotamig (GR1803)Cullinan Therapeutics Inc., Genrix Bio, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.Multiple MyelomaPhase 3NCT07452198
2029-03 (month only)Nab-paclitaxelBristol-Myers SquibbThymoma and Thymic CarcinomaPhase 2/3NCT07463313
2029-03 (month only)MitapivatAGIOS PHARMACEUTICALS, INC., Avanzanite BioscienceNon-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-ThalassemiaPhase 3NCT07517133
2029-03 (month only)Lenacapavir (Sunlenca), Teropavimab, ZinlirvimabGilead SciencesHIVPhase 3NCT07682961
2029-03 (month only)Lenacapavir (Sunlenca), Teropavimab, ZinlirvimabGilead SciencesHIVPhase 3NCT07683000
2029-03 (month only)Sintilimab, CapecitabineInnovent Biologics, Cheplapharm Arzneimittel GmbHAnal Squamous Cell Carcinoma, Limited-stagePhase 3NCT07692152
2029-03 (month only)Daraxonrasib, ZoldonrasibBeOne Medicines, Revolution MedicinesPancreatic Ductal Adenocarcinoma, Pancreatic CancerPhase 3NCT07805954
2029-03 (month only)UBT251Novo Nordisk, United Bio-Technology (Hengqin)ObesityPhase 3NCT07806851
2029-03 (month only)EmpagliflozinBoehringer Ingelheim, Eli LillyParaffinoma, Granuloma, Foreign-BodyPhase 2/3NCT07828002
2029-03 (month only)7MW3711Mabwell BioscienceNon-Small Cell Lung CancerPhase 3NCT07831863
2029-03-03Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabSchizophreniaPhase 3NCT07686263
2029-03-03ALN-CIDEBAlnylam Pharmaceuticals, Regeneron PharmaceuticalsMASH / NASHPhase 3NCT07854782
2029-03-06FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsNasal PolypsPhase 3NCT07782957
2029-03-06FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsNasal PolypsPhase 3NCT07782970
2029-03-10CapecitabineCheplapharm Arzneimittel GmbHGastric CancerPhase 3NCT06313567
2029-03-13tezepelumabAmgen, AstraZenecaChronic Obstructive Pulmonary DiseasePhase 3NCT06878261
2029-03-13tezepelumabAmgen, AstraZenecaChronic Obstructive Pulmonary DiseasePhase 3NCT06883305
2029-03-14Cabotegravir (Apretude)ViiV HealthcareHIVPhase 3NCT06134362
2029-03-14BerobenatidePfizerObesityPhase 3NCT07794761
2029-03-15IberdomideBristol-Myers SquibbMultiple MyelomaPhase 3NCT05827016
2029-03-15metforminIdiopathic Pulmonary FibrosisPhase 3NCT07520110
2029-03-15Vatiquinone (PTC743)PTC TherapeuticsFriedreich AtaxiaPhase 3NCT07681713
2029-03-17JSKN016Alphamab OncologyTriple Negative Breast CancerPhase 3NCT07533123
2029-03-19DostarlimabGlaxoSmithKlineColonic Neoplasms, Neoplasms, ColonPhase 3NCT05855200
2029-03-19metforminPre-Eclampsia Onset Less Than 37 Weeks, Pre-Eclampsia, Pre-EclampsiaPhase 3NCT06452498
2029-03-27Rimegepant (Nurtec ODT)Eisai, PfizerMigrainePhase 3NCT05156398
2029-03-27MethylprednisolonePfizerHepatectomyPhase 3NCT07507643
2029-03-28Cetuximab, CalderasibEli Lilly, Merck KGaA, Merck & Co.Colon Adenocarcinoma, Rectal AdenocarcinomaPhase 3NCT06997497
2029-03-28Cenvacibart, AmrecibartRegeneron PharmaceuticalsAtrial Fibrillation (AF)Phase 3NCT07430956
2029-03-30remibrutinibNovartisIgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg AllergyPhase 3NCT07768371
2029-03-31PembrolizumabMerck & Co.Head and Neck Squamous Cell CarcinomaPhase 3NCT05721755
2029-03-31Fulvestrant, Palbociclib, Letrozole, GedatolisibAstraZeneca, Pfizer, NovartisHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT06757634
2029-03-31Semaglutide (Ozempic)Novo NordiskAlcohol Use DisorderPhase 3NCT07218354
2029-03-31Pembrolizumab, Nivolumab, Brentuximab VedotinMerck & Co., Bristol-Myers Squibb, Ono PharmaceuticalRecurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaPhase 2/3NCT07572123

April 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-04 (month only)certolizumab pegolUCBRecurrent Unexplained Implantation FailurePhase 3NCT05930613
2029-04 (month only)risankizumabAbbVie, Boehringer IngelheimCrohn's DiseasePhase 3NCT05995353
2029-04 (month only)RemlifanserinAcadia PharmaceuticalsAlzheimer's Disease, Alzheimer's Disease PsychosisPhase 3NCT06194799
2029-04 (month only)TislelizumabBeOne MedicinesCancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer, Soft Tissue SarcomaPhase 3NCT06332274
2029-04 (month only)PembrolizumabMerck & Co.GlioblastomaPhase 3NCT06556563
2029-04 (month only)RemternetugEli LillyAlzheimer's DiseasePhase 3NCT06653153
2029-04 (month only)PumitamigBioNTech, Bristol-Myers SquibbSmall Cell Lung CancerPhase 3NCT06712355
2029-04 (month only)Soficitinib (ICP-332)Beijing InnoCare Pharma Tech Co.Non Segmental VitiligoPhase 2/3NCT07047612
2029-04 (month only)HRS-4642Jiangsu Hengrui PharmaceuticalsPancreatic CancerPhase 3NCT07232875
2029-04 (month only)BGB-43395, LetrozoleBeOne Medicines, NovartisHR+/HER2- Metastatic Breast CancerPhase 3NCT07492641
2029-04 (month only)PonesimodLaboratoires Juvisé Pharmaceuticals, Vanda PharmaceuticalsUlcerative ColitisPhase 3NCT07686081
2029-04 (month only)HRS-1780Jiangsu Hengrui PharmaceuticalsUncontrolled or Resistant HypertensionPhase 2/3NCT07708441
2029-04 (month only)IfebemtinibBoehringer Ingelheim, InxMedNon-Small Cell Lung CancerPhase 3NCT07833202
2029-04-01Nivolumab, RituximabBristol-Myers Squibb, Ono Pharmaceutical, BiogenPrimary Mediastinal LymphomaPhase 3NCT06188676
2029-04-01CPO301Conjupro Biotherapeutics, Inc.Breast CancerPhase 3NCT07406542
2029-04-02DepemokimabGlaxoSmithKlineChronic Obstructive Pulmonary DiseasePhase 3NCT07177339
2029-04-02enicepatideChugai Pharma, RocheType 2 DiabetesPhase 3NCT07889648
2029-04-09AbataceptBristol-Myers SquibbMyocarditis Acute, CancerPhase 3NCT05335928
2029-04-10abrocitinibPfizerAtopic DermatitisPhase 3NCT07823595
2029-04-16InclisiranAlnylam Pharmaceuticals, NovartisAtherosclerotic Cardiovascular DiseasePhase 3NCT05739383
2029-04-23Sotiburafusp alfaHuabo Biopharm Co.Endometrial CancerPhase 3NCT07902999
2029-04-25Semaglutide (Wegovy)Novo NordiskMASH / NASHPhase 3NCT04822181
2029-04-27Rilvegostomig, Trastuzumab Deruxtecan, CapecitabineAstraZeneca, COMPUGEN LTD, Daiichi SankyoGastric CancerPhase 3NCT06764875
2029-04-27Sacituzumab Tirumotecan, DexamethasoneMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Ovarian CancerPhase 3NCT06824467
2029-04-27Nerandomilast (Jascayd)Boehringer IngelheimFibrosing Interstitial Lung DiseasePhase 3NCT07366034
2029-04-28Fruquintinib, CapecitabineHUTCHMED, Takeda Pharmaceutical Company, Cheplapharm Arzneimittel GmbHColorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal CancerPhase 3NCT07885384
2029-04-29RamantamigJohnson & JohnsonMultiple MyelomaPhase 3NCT07518186
2029-04-29survodutideBoehringer Ingelheim, Zealand PharmaObesity, MASH / NASHPhase 3NCT07850063
2029-04-29ensifentrineMerck & Co., Nuance PharmaChronic Obstructive Pulmonary DiseasePhase 3NCT07874815
2029-04-30Tirzepatide (Mounjaro), PioglitazoneEli Lilly, Tanabe Pharma Corporation, Takeda Pharmaceutical CompanyType 2 DiabetesPhase 3NCT06246799
2029-04-30TolebrutinibSanofiMultiple SclerosisPhase 3NCT06372145
2029-04-30Atezolizumab, Pembrolizumab, Nivolumab, pemetrexed, DocetaxelChugai Pharma, Roche, Merck & Co.Non-Small Cell Lung CancerPhase 3NCT06632327
2029-04-30ElriterceptTakeda Pharmaceutical CompanyMyelodysplastic SyndromesPhase 3NCT07422480
2029-04-30Cetuximab, BevacizumabEli Lilly, Merck KGaA, RocheRectal Adenocarcinoma, High-Risk Cancer, MSSPhase 3NCT07549399

May 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-05 (month only)N-acetylcysteineApotex Inc., Phebra Pty LtdRetinitis PigmentosaPhase 3NCT05537220
2029-05 (month only)zanubrutinibBeOne MedicinesSplenic Marginal Zone LymphomaPhase 3NCT05735834
2029-05 (month only)OlomorasibEli LillyNon-Small Cell Lung CancerPhase 3NCT06890598
2029-05 (month only)OsavampatorNeurocrine Biosciences, Takeda Pharmaceutical CompanyMajor Depressive DisorderPhase 3NCT06966401
2029-05 (month only)TersolisibEli LillyHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07174336
2029-05 (month only)Bevacizumab, Telisotuzumab AdizutecanRoche, AbbVieColorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal CancerPhase 3NCT07525206
2029-05 (month only)Delpacibart zotadirsenNovartisMuscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease, Musculoskeletal Diseases, Neuromuscular Diseases (NMD), Nervous System Diseases, Genetic Diseases, X-Linked, Hereditary, Neonatal Disease, Duchene Muscular Dystrophy, Congenital, DMDPhase 3NCT07587242
2029-05 (month only)ToripalimabCoherus BioSciences, Inc., Shanghai Junshi BioscienceNon-Small Cell Lung CancerPhase 3NCT07608159
2029-05 (month only)safusidenibNuvation BioGliomaPhase 3NCT07712757
2029-05-01TislelizumabBeOne MedicinesLaryngeal Carcinoma, Hypopharyngeal CarcinomaPhase 3NCT06957938
2029-05-01metforminCOPDPhase 3NCT06999343
2029-05-01Capecitabine, BizrolertinibCheplapharm Arzneimittel GmbH, RocheHER2-Positive Breast CancerPhase 2/3NCT07413939
2029-05-01Disitamab VedotinPfizer, RemeGen Co., Ltd.Urothelial CarcinomaPhase 3NCT07498907
2029-05-03NavlimetostatBristol-Myers SquibbPancreatic Ductal AdenocarcinomaPhase 2/3NCT07076121
2029-05-04FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsAsthmaPhase 3NCT07782996
2029-05-10DaraxonrasibBeOne Medicines, Revolution MedicinesPancreatic Ductal AdenocarcinomaPhase 3NCT07252232
2029-05-11Pembrolizumab, Datopotamab DeruxtecanMerck & Co., AstraZeneca, Daiichi SankyoNon-Small Cell Lung CancerPhase 3NCT05555732
2029-05-14duvakitugSanofi, Teva Pharmaceutical IndustriesCrohn's DiseasePhase 3NCT07184931
2029-05-14Nerandomilast (Jascayd)Boehringer IngelheimFamilial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung DiseasesPhase 3NCT07201922
2029-05-21Carfilzomib, Daratumumab, Pomalidomide, Bortezomib, Linvoseltamab, DexamethasoneAmgen, Ono Pharmaceutical, Johnson & JohnsonMultiple MyelomaPhase 3NCT07222761
2029-05-26UlotarontOtsuka HoldingsGeneralized Anxiety DisorderPhase 3NCT07786454
2029-05-29Doravirine/islatravir (Idvynso)Merck & Co.HIVPhase 3NCT04776252
2029-05-30tofacitinib, Abatacept, tocilizumabPfizer, Bristol-Myers Squibb, Chugai PharmaPolyarticular Course Juvenile Idiopathic Arthritis (JIA)Phase 3NCT06654882
2029-05-31ElafibranorGenfit, IpsenPrimary Biliary CholangitisPhase 3NCT06016842
2029-05-31Fulvestrant, Dalpiciclib, JS105AstraZeneca, Jiangsu Hengrui Pharmaceuticals, Risen (Suzhou) Pharma Tech Co., Ltd.HR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07207070
2029-05-31TelitaciceptRemeGen Co., Ltd., Vor BioCTD-ILDPhase 3NCT07495033
2029-05-31IBI3003Innovent BiologicsMultiple MyelomaPhase 3NCT07623798
2029-05-31MethotrexateRheumatoid ArthritisPhase 2/3NCT07627893
2029-05-31Freneslerbart/mevonlerbartRegeneron PharmaceuticalsAllergic Conjunctivitis, Cat AllergyPhase 3NCT07675811

June 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-06 (month only)upadacitinibAbbVieJuvenile Idiopathic ArthritisPhase 3NCT05609630
2029-06 (month only)Iparomlimab and tuvonralimabQilu PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT05690945
2029-06 (month only)DocetaxelSanofiHormone Receptor Positive HER-2 Negative Breast CancerPhase 3NCT05901428
2029-06 (month only)Sacituzumab GovitecanGilead SciencesEndometrial CancerPhase 3NCT06486441
2029-06 (month only)LisaftoclaxAscentage Pharma Group Inc.Higher-risk Myelodysplastic SyndromePhase 3NCT06641414
2029-06 (month only)RevumenibSyndaxAcute Myeloid LeukemiaPhase 3NCT07211958
2029-06 (month only)AzetukalnerXenon PharmaceuticalsBipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II DisorderPhase 3NCT07217860
2029-06 (month only)DonidalorsenIonis Pharmaceuticals, Otsuka Holdings, TheratechnologiesHereditary AngioedemaPhase 3NCT07298447
2029-06 (month only)Imatinib mesylate prodrug (IkT-001Pro)Inhibikase TherapeuticsPulmonary Arterial HypertensionPhase 3NCT07365332
2029-06 (month only)BMN 333BioMarin PharmaceuticalAchondroplasiaPhase 2/3NCT07441876
2029-06 (month only)MitapivatAGIOS PHARMACEUTICALS, INC., Avanzanite BioscienceTransfusion-Dependent Beta ThalassemiaPhase 3NCT07506863
2029-06 (month only)TSC-101TScan Therapeutics, Inc.Hematologic MalignanciesPhase 3NCT07702578
2029-06 (month only)Serplulimab, Tambotatug pelitecanAbbott, Accord Healthcare, EisaiSmall Cell Lung CancerPhase 3NCT07739758
2029-06 (month only)Darunavir, Dolutegravir, tenofovir alafenamide (Vemlidy), Emtricitabine (Emtriva)Johnson & Johnson, Shionogi, ViiV HealthcareHIVPhase 3NCT07792096
2029-06 (month only)JADE101Jade Biosciences, Inc.IgA NephropathyPhase 3NCT07902817
2029-06-01Datopotamab DeruxtecanAstraZeneca, Daiichi SankyoUrothelial CarcinomaPhase 2/3NCT07129993
2029-06-01PlinabulinBeyondSpring Pharmaceuticals, Jiangsu Hengrui PharmaceuticalsNon-Small Cell Lung CancerPhase 3NCT07361484
2029-06-01AtezolizumabChugai Pharma, RocheHepatocellular CarcinomaPhase 3NCT07461675
2029-06-01Sutantatug envedotinCorbus Pharmaceuticals, CSPC Megalith BiopharmaceuticalUrothelial CarcinomaPhase 3NCT07526792
2029-06-01PF-08634404Pfizer, Shenyang Sunshine PharmaceuticalEndometrial CancerPhase 3NCT07578649
2029-06-01tilrekimigPfizerAsthmaPhase 3NCT07772921
2029-06-04SarilumabRegeneron Pharmaceuticals, SanofiPolymyalgia RheumaticaPhase 3NCT07286214
2029-06-04Zadavotide guraxetanAstraZenecaMetastatic Castration-Resistant Prostate CancerPhase 3NCT07611110
2029-06-05survodutideBoehringer Ingelheim, Zealand PharmaMASH / NASHPhase 3NCT06632457
2029-06-07tilrekimigPfizerAsthmaPhase 3NCT07869043
2029-06-15INCA033989IncyteEssential ThrombocythemiaPhase 3NCT07623200
2029-06-18Pembrolizumab, AmivantamabMerck & Co., Genmab, Johnson & JohnsonHead and Neck Squamous Cell CarcinomaPhase 3NCT07276399
2029-06-19etrasimodEverest Medicines (Beijing) Co., Ltd., PfizerUlcerative ColitisPhase 3NCT03950232
2029-06-22bleximenibJohnson & JohnsonAcute Myeloid LeukemiaPhase 3NCT06852222
2029-06-22Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabAlzheimer's DiseasePhase 3NCT06937229
2029-06-25Cenvacibart, AmrecibartRegeneron PharmaceuticalsVenous ThromboembolismPhase 3NCT07697599
2029-06-26LitifilimabBiogenSubacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus ErythematosusPhase 3NCT06044337
2029-06-26zenagamtideNovo NordiskObesityPhase 3NCT07339423
2029-06-27PovetaciceptVertex PharmaceuticalsPrimary Membranous NephropathyPhase 2/3NCT07204275
2029-06-29CoramitugNovo NordiskHeart FailurePhase 3NCT07207811
2029-06-30BevacizumabRocheAdvanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Phase 3NCT04181060
2029-06-30Gilteritinib, Gemtuzumab Ozogamicin, Vyxeos, MethotrexateAstellas Pharma, Pfizer, HandokAcute Myeloid LeukemiaPhase 3NCT04293562
2029-06-30CetuximabEli Lilly, Merck KGaAMetastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal CarcinomaPhase 3NCT05863195
2029-06-30Semaglutide (Wegovy)Novo NordiskKidney Transplant RecipientPhase 2/3NCT06913023
2029-06-30ZanzalintinibExelixisPancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)Phase 2/3NCT06943755
2029-06-30DurvalumabAstraZenecaSmall Cell Lung CancerPhase 3NCT06992609
2029-06-30Purinostat MesylateChengdu Zenitar Biomedical TechnologyDiffuse Large B-Cell LymphomaPhase 3NCT07011056
2029-06-30PrasinezumabProthena Biosciences Limited, RocheParkinson's DiseasePhase 3NCT07174310
2029-06-30Tislelizumab, Disitamab VedotinBeOne Medicines, Pfizer, RemeGen Co., Ltd.Gastric CarcinomaPhase 3NCT07315750
2029-06-30EverolimusNovartisLiver Allograft, Liver Diseases, Liver TransplantationPhase 3NCT07739914

July 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-07 (month only)CadonilimabAkesoGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaPhase 3NCT07023315
2029-07 (month only)DireclidineNeurocrine Biosciences, Nxera PharmaSchizophreniaPhase 3NCT07227818
2029-07 (month only)Treprostinil (L606)Liquidia Corporation, Pharmosa Biopharm Inc.Pulmonary Hypertension Associated with Interstitial Lung DiseasePhase 3NCT07285655
2029-07 (month only)N-acetylcysteineApotex Inc., Phebra Pty LtdRetinitis Pigmentosa (RP), Usher SyndromePhase 3NCT07290530
2029-07 (month only)RAP-219Rapport Therapeutics, Inc., Tenacia BiotechnologyEpilepsy, Focal Onset SeizuresPhase 3NCT07563881
2029-07 (month only)RAP-219Rapport Therapeutics, Inc., Tenacia BiotechnologyEpilepsy, Focal Onset SeizuresPhase 3NCT07594119
2029-07 (month only)zelicapavirEnanta Pharmaceuticals, Inc.RSVPhase 2/3NCT07908381
2029-07-01Semaglutide (Ozempic), Sotagliflozin (Inpefa), FinerenoneNovo Nordisk, Lexicon Pharmaceuticals, ViatrisHeart Failure, Type 1 DiabetesPhase 3NCT06082063
2029-07-01Hydroxychloroquine, Anastrozole, Palbociclib, Letrozole, ExemestaneAdvanz Pharma, ANI Pharmaceuticals, Inc., AstraZenecaHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT07061717
2029-07-01Bevacizumab, SerplulimabRoche, Abbott, Accord HealthcareNon-Resectable Pancreas CarcinomaPhase 3NCT07235930
2029-07-01Raludotatug DeruxtecanDaiichi Sankyo, Merck & Co.Ovarian CancerPhase 3NCT07791732
2029-07-02crizanlizumab-tmca (Adakveo)NovartisSickle Cell DiseasePhase 3NCT06439082
2029-07-02Methylprednisolone, Rituximab, Zilovertamab vedotinPfizer, Biogen, Chugai PharmaDiffuse Large B-Cell LymphomaPhase 3NCT06717347
2029-07-15Avelumab, CabozantinibMerck KGaA, Exelixis, IpsenUrothelial CarcinomaPhase 3NCT05092958
2029-07-15Iparomlimab and tuvonralimab, Iparomlimab (QL1604)Qilu PharmaceuticalLocal Advanced Rectal Cancer, Radiotherapy, ImmunotherapyPhase 3NCT07686640
2029-07-20NIO752NovartisProgressive Supranuclear PalsyPhase 3NCT07498426
2029-07-20FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsChronic Obstructive Pulmonary DiseasePhase 3NCT07780656
2029-07-20FelcorekibartGlaxoSmithKline, Jiangsu Hengrui PharmaceuticalsChronic Obstructive Pulmonary DiseasePhase 3NCT07780669
2029-07-21Durvalumab, Nab-paclitaxelAstraZeneca, Bristol-Myers SquibbBladder CancerPhase 2/3NCT06214572
2029-07-21MavacamtenBristol-Myers SquibbHypertrophic CardiomyopathyPhase 3NCT07940777
2029-07-23zenagamtideNovo NordiskObesityPhase 3NCT07567001
2029-07-23Pembrolizumab, Dostarlimab, GSK 5733584Merck & Co., GlaxoSmithKlineEndometrial CancerPhase 3NCT07684599
2029-07-25remibrutinibNovartisMultiple SclerosisPhase 3NCT06846281
2029-07-27Sacituzumab TirumotecanMerck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Bladder CancerPhase 3NCT07419295
2029-07-29OdronextamabRegeneron PharmaceuticalsFollicular LymphomaPhase 3NCT06097364
2029-07-29MezagitamabTakeda Pharmaceutical CompanyImmune Thrombocytopenic Purpura (ITP)Phase 3NCT06948318
2029-07-30Vanzacaftor / tezacaftor / deutivacaftorVertex PharmaceuticalsCystic FibrosisPhase 3NCT05844449
2029-07-30BudesonideAstraZenecaAsthmaPhase 3NCT07934420
2029-07-31Venetoclax, AcalabrutinibAbbVie, Roche, AstraZenecaCLLPhase 2/3NCT03868722
2029-07-31RilvegostomigAstraZeneca, COMPUGEN LTDBiliary Tract CancerPhase 3NCT07221253
2029-07-31Ribociclib, Anastrozole, Letrozole, ExemestaneNovartis, ANI Pharmaceuticals, Inc., AstraZenecaBreast CancerPhase 3NCT07391774
2029-07-31VonaprumentAnnexon, Inc.Age-Related Macular Degeneration, Geographic AtrophyPhase 3NCT07807969

August 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-08 (month only)Carfilzomib, Lenalidomide, Elotuzumab, DexamethasoneAmgen, Ono Pharmaceutical, Bristol-Myers SquibbMultiple MyelomaPhase 3NCT03948035
2029-08 (month only)EplontersenAstraZeneca, Ionis PharmaceuticalsHereditary Transthyretin-Mediated Amyloid PolyneuropathyPhase 3NCT05071300
2029-08 (month only)EplontersenAstraZeneca, Ionis PharmaceuticalsTransthyretin Amyloidosis with CardiomyopathyPhase 3NCT05667493
2029-08 (month only)Tamoxifen (Soltamox), Anastrozole, Letrozole, Elacestrant, ExemestaneMayne Pharma, Rosemont Pharmaceuticals, ANI Pharmaceuticals, Inc.Breast CancerPhase 3NCT06492616
2029-08 (month only)AnnamycinMoleculinAcute Myeloid LeukemiaPhase 2/3NCT06788756
2029-08 (month only)Rinatabart sesutecan (Rina-S)GenmabEndometrial CancerPhase 3NCT07166094
2029-08 (month only)DapagliflozinAstraZeneca, Ono PharmaceuticalSeptic ShockPhase 3NCT07488689
2029-08 (month only)MitapivatAGIOS PHARMACEUTICALS, INC., Avanzanite BioscienceSickle Cell DiseasePhase 3NCT07656415
2029-08 (month only)orforglipronChugai Pharma, Eli LillyObesity, HypertensionPhase 3NCT07794579
2029-08-01NiraparibGlaxoSmithKline, Zai LabOvarian CancerPhase 3NCT05659381
2029-08-01mazdutideEli Lilly, Innovent BiologicsType 2 DiabetesPhase 3NCT07083154
2029-08-04FitusiranAlnylam Pharmaceuticals, SanofiHemophiliaPhase 3NCT07285460
2029-08-05zasocitinibTakeda Pharmaceutical CompanyPsoriasisPhase 3NCT06550076
2029-08-06Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabIrritability Associated With Autism Spectrum DisorderPhase 3NCT07284745
2029-08-06Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabIrritability Associated With Autism Spectrum DisorderPhase 3NCT07285798
2029-08-13duvakitugSanofi, Teva Pharmaceutical IndustriesCrohn's DiseasePhase 3NCT07184944
2029-08-13Cabotegravir/rilpivirine (Cabenuva)ViiV HealthcareHIVPhase 3NCT07650916
2029-08-15GabapentinPfizer, ViatrisHead and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Phase 3NCT06992427
2029-08-15Methylprednisolone, FrexalimabPfizer, SanofiKidney Transplant RejectionPhase 2/3NCT07412470
2029-08-15VAY736NovartisSjögren's DiseasePhase 3NCT07621809
2029-08-16Nivolumab, Rilvegostomig, Capecitabine, Sonesitatug vedotinBristol-Myers Squibb, Ono Pharmaceutical, AstraZenecaGastric CancerPhase 3NCT07431281
2029-08-18tezepelumabAmgen, AstraZenecaAsthmaPhase 3NCT07013123
2029-08-18Cenvacibart, AmrecibartRegeneron PharmaceuticalsPeripheral Artery Disease (PAD)Phase 3NCT07318610
2029-08-18CadonilimabAkesoGastric / Gastroesophageal Junction AdenocarcinomaPhase 3NCT07700979
2029-08-20VericiguatBayer, Merck & Co.Heart FailurePhase 2/3NCT05714085
2029-08-30LurbinectedinJazz Pharmaceuticals, Luye Pharma Group, Merck KGaALeiomyosarcomaPhase 3NCT06088290
2029-08-31SetidegrasibAstellas PharmaPancreatic Ductal AdenocarcinomaPhase 3NCT07409272
2029-08-31CapecitabineCheplapharm Arzneimittel GmbHNewly Diagnosed Triple-negative Breast CancerPhase 3NCT07869628

September 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-09 (month only)BevacizumabRocheColorectal Cancer, Metastatic Colorectal CancerPhase 3NCT04188145
2029-09 (month only)Pembrolizumab, Sacituzumab GovitecanMerck & Co., Gilead SciencesBreast CancerPhase 3NCT06081244
2029-09 (month only)PembrolizumabMerck & Co.Solid Tumors, Urothelial CarcinomaPhase 2/3NCT06493552
2029-09 (month only)SunvozertinibAstraZeneca, Dizal PharmaceuticalsNon-Small Cell Lung CancerPhase 3NCT07182682
2029-09 (month only)BuntanetapAnnovis Bio (NYSE American: ANVS)Parkinson's DiseasePhase 2/3NCT07284784
2029-09 (month only)ADSTEMEHL BioAtopic DermatitisPhase 3NCT07377838
2029-09 (month only)DonanemabEli LillyAlzheimer's DiseasePhase 3NCT07602582
2029-09 (month only)Bevacizumab, Trastuzumab rezetecanRoche, Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui PharmaceuticalsColorectal CancerPhase 3NCT07676162
2029-09 (month only)Tislelizumab, RamucirumabBeOne Medicines, Eli LillyGastroesophageal AdenocarcinomaPhase 3NCT07763171
2029-09-01Nab-paclitaxel, S-1Bristol-Myers Squibb, Nordic Group B.V., Taiho PharmaceuticalBiliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase InhibitorPhase 2/3NCT06662877
2029-09-03elecoglipronAstraZeneca, EccogeneHeart FailurePhase 3NCT07761117
2029-09-06GSK 5733584GlaxoSmithKlineOvarian CancerPhase 3NCT07694427
2029-09-07BlinatumomabAmgenAcute Lymphoblastic LeukemiaPhase 3NCT04994717
2029-09-07Ribociclib, Goserelin, Letrozole, ExemestaneNovartis, AstraZeneca, TerSera Therapeutics LLCBreast CancerPhase 3NCT05827081
2029-09-07AdagrasibBristol-Myers Squibb, Zai LabNon-Small Cell Lung CancerPhase 3NCT06875310
2029-09-07cagrilintide/semaglutideNovo NordiskType 2 DiabetesPhase 3NCT07282613
2029-09-11CenvacibartRegeneron PharmaceuticalsAtrial Fibrillation (AF)Phase 3NCT07626411
2029-09-14Durvalumab, TremelimumabAstraZeneca, MedImmune LLCHepatocellular CarcinomaPhase 2/3NCT06904170
2029-09-14BelumosudilKadmon Corporation, Meiji Seika Pharma, SanofiGraft-versus-Host Disease, Chronic Graft-versus-Host DiseasePhase 3NCT07771439
2029-09-15BevacizumabRocheNon-Small Cell Lung CancerPhase 3NCT07481786
2029-09-18CetrelimabJohnson & JohnsonBladder CancerPhase 3NCT05714202
2029-09-20LumateperoneIntra-Cellular Therapies, Johnson & JohnsonMajor Depressive DisorderPhase 3NCT07747389
2029-09-21BGB-B2033BeOne MedicinesHepatocellular CarcinomaPhase 3NCT07836530
2029-09-22LetrozoleNovartisCarcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of OvaryPhase 3NCT05601700
2029-09-30Glecirasib, SitneprotafibAllist Pharmaceuticals, Jacobio PharmaceuticalsNon-Small Cell Lung CancerPhase 3NCT06416410
2029-09-30Nab-paclitaxel, Cetuximab, ToripalimabBristol-Myers Squibb, Eli Lilly, Merck KGaAHead and Neck Squamous Cell CarcinomaPhase 3NCT06647563
2029-09-30Obinutuzumab, Sonrotoclax, RituximabRoche, BeOne Medicines, BiogenChronic Lymphocytic LeukemiaPhase 3NCT06943872
2029-09-30VortioxetineH. Lundbeck, Takeda Pharmaceutical CompanyMajor Depressive DisorderPhase 3NCT07204314
2029-09-30ToripalimabCoherus BioSciences, Inc., Shanghai Junshi BioscienceCervical Cancer MetastaticPhase 3NCT07392060
2029-09-30ChidamideChipscreen Biosciences, GNT Biotech & Medicals, HUYABIO International, LLC.Diffuse Large B-Cell LymphomaPhase 3NCT07493109
2029-09-30DexamethasoneAcute Respiratory Distress Syndrome (ARDS)Phase 3NCT07576660
2029-09-30TemozolomideMerck & Co.GlioblastomaPhase 2/3NCT07605364
2029-09-30CPO301, EnlonstobartConjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd.Non-Small Cell Lung CancerPhase 3NCT07672223
2029-09-30DexamethasoneHemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic LymphohistiocytosisPhase 3NCT07861776

October 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-10 (month only)Atezolizumab, Capmatinib, Trametinib, Alectinib, Cobimetinib, Entrectinib, Dabrafenib, Pertuzumab, VemurafenibChugai Pharma, Roche, IncyteHaematological Malignancy, Solid TumourPhase 2/3NCT05722886
2029-10 (month only)Cobimetinib, VemurafenibExelixis, RocheMelanomaPhase 2/3NCT05768178
2029-10 (month only)AlectinibChugai Pharma, RocheHaematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma, Solid TumourPhase 2/3NCT05770037
2029-10 (month only)AtezolizumabChugai Pharma, RocheColorectal Cancer, MelanomaPhase 2/3NCT05770102
2029-10 (month only)EntrectinibChugai Pharma, RocheHaematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma, Solid TumourPhase 2/3NCT05770544
2029-10 (month only)PertuzumabRocheHaematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm, Solid TumourPhase 2/3NCT05786716
2029-10 (month only)DurvalumabAstraZenecaNon-Small Cell Lung CancerPhase 3NCT06284317
2029-10 (month only)Sacituzumab Govitecan, LurbinectedinGilead Sciences, Jazz Pharmaceuticals, Luye Pharma GroupSmall Cell Lung CancerPhase 3NCT06801834
2029-10 (month only)CapmatinibIncyte, NovartisSolid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Malignancy, Glioma, Neuroblastoma, Gastric Cancer, Soft Tissue SarcomaPhase 2/3NCT06988475
2029-10 (month only)Camrelizumab, ApatinibElevar Therapeutics, Inc., Jiangsu Hengrui Pharmaceuticals, Advenchen LaboratoriesHepato Cellular Carcinoma (HCC), Chemotherapy EffectPhase 3NCT07267806
2029-10 (month only)Trametinib, DabrafenibNovartisGliomaPhase 2/3NCT07440290
2029-10 (month only)Pirtobrutinib, bexobrutidegEli Lilly, Nurix Therapeutics, Inc., RocheChronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic LeukemiaPhase 3NCT07516093
2029-10 (month only)ZoldonrasibRevolution MedicinesNon-Small Cell Lung CancerPhase 3NCT07777822
2029-10 (month only)eloralintide, Tirzepatide (Zepbound)Eli LillyObesityPhase 3NCT07881432
2029-10 (month only)eloralintide, Tirzepatide (Zepbound)Eli LillyObesityPhase 3NCT07881458
2029-10-01PembrolizumabMerck & Co.Gastric CancerPhase 3NCT06093425
2029-10-01ZipalertinibCullinan Therapeutics Inc., Taiho PharmaceuticalNon-Small Cell Lung CancerPhase 3NCT07128199
2029-10-01ToripalimabCoherus BioSciences, Inc., Shanghai Junshi BioscienceEsophageal CancerPhase 3NCT07332221
2029-10-01Sintilimab, IpilimumabInnovent Biologics, Bristol-Myers Squibb, Ono PharmaceuticalLocally Advanced Rectal Cancer (LARC)Phase 2/3NCT07879586
2029-10-01Sintilimab, IpilimumabInnovent Biologics, Bristol-Myers Squibb, Ono PharmaceuticalLocally Advanced Rectal Cancer (LARC)Phase 2/3NCT07879599
2029-10-01CPO301, EnlonstobartConjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd.Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal CarcinomaPhase 3NCT07925021
2029-10-03RiliprubartSanofiPolyneuropathy, Inflammatory Demyelinating, ChronicPhase 3NCT06859099
2029-10-12deucravacitinibBristol-Myers SquibbPsoriasisPhase 3NCT06979453
2029-10-16Bevacizumab, precemtabart tocentecanRoche, Merck KGaAColorectal Cancer, Metastatic Colorectal CancerPhase 3NCT07549412
2029-10-26Intismeran AutogeneMerck & Co., ModernaMelanomaPhase 3NCT05933577
2029-10-26LaroprovstatAstraZenecaAtherosclerotic Cardiovascular DiseasePhase 3NCT07000357
2029-10-30JS207Shanghai Junshi BioscienceHepatocellular CarcinomaPhase 3NCT07823348
2029-10-31TemozolomideMerck & Co.GliomaPhase 3NCT00887146

November 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-11 (month only)alprostadilBiopeutics, PfizerHeart FailurePhase 3NCT00610051
2029-11 (month only)Bevacizumab, RegorafenibRoche, BayerColorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal CancerPhase 2/3NCT05462613
2029-11 (month only)upadacitinibAbbVieAtopic DermatitisPhase 3NCT06461897
2029-11 (month only)Inobrodib, Pomalidomide, DexamethasoneCellCentric Ltd., Bristol-Myers SquibbMultiple MyelomaPhase 3NCT07772024
2029-11 (month only)eloralintideEli LillyObesityPhase 3NCT07900633
2029-11-01Gemcitabine, DocetaxelEli Lilly, SanofiNon-muscle-invasive Bladder CancerPhase 3NCT05538663
2029-11-01DurvalumabAstraZenecaGastric, Esophagogastric JunctionPhase 3NCT07877818
2029-11-06survodutideBoehringer Ingelheim, Zealand PharmaObesityPhase 3NCT07855900
2029-11-15Tislelizumab, Brentuximab VedotinBeOne Medicines, Pfizer, SeagenClassical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET ScanPhase 2/3NCT06563245
2029-11-16BrivaracetamUCBEpilepsyPhase 3NCT06315322
2029-11-27lunsekimigSanofiChronic Obstructive Pulmonary DiseasePhase 3NCT07190209
2029-11-27lunsekimigSanofiChronic Obstructive Pulmonary DiseasePhase 3NCT07190222
2029-11-29EnlicitideMerck & Co.Atherosclerotic Cardiovascular DiseasePhase 3NCT06008756
2029-11-30FinerenoneBayerHeart FailurePhase 3NCT07188805
2029-11-30FenebrutinibRocheMultiple SclerosisPhase 3NCT07937852

December 2029

Primary completionDrugDeveloperIndicationPhaseStudy
2029-12 (month only)GivinostatItalfarmaco S.p.A., JCR PharmaceuticalsDuchenne Muscular DystrophyPhase 2/3NCT03373968
2029-12 (month only)AbataceptBristol-Myers SquibbGiant Cell ArteritisPhase 3NCT04474847
2029-12 (month only)Treprostinil (Tyvaso)United TherapeuticsIdiopathic Pulmonary FibrosisPhase 3NCT04905693
2029-12 (month only)RilparencelProKidneyChronic Kidney DiseasePhase 3NCT05099770
2029-12 (month only)GanaxoloneImmedica Pharma ABCDKL5 Deficiency DisorderPhase 3NCT05249556
2029-12 (month only)Lenalidomide, Rituximab, EpcoritamabBristol-Myers Squibb, Celgene Corporation, BiogenFollicular LymphomaPhase 3NCT05409066
2029-12 (month only)baricitinibEli Lilly, IncyteActive Non-anterior Non-infectious UveitisPhase 3NCT05651880
2029-12 (month only)SugemalimabCStone Pharmaceuticals, Ewopharma, Istituto Gentili S.R.L.Extranodal NK/T-cell LymphomaPhase 3NCT05700448
2029-12 (month only)OrdastobartElpiscience (Suzhou) Biopharma, Ltd., Inhibrx Biosciences, IncHead and Neck Squamous Cell CarcinomaPhase 2/3NCT06295731
2029-12 (month only)neladalkibGlaxoSmithKline, Nuvalent, Inc.Non-Small Cell Lung CancerPhase 3NCT06765109
2029-12 (month only)VisugromabCatalYm GmbHCancer-associated CachexiaPhase 2/3NCT07112196
2029-12 (month only)OlverembatinibAscentage Pharma Group Inc., Innovent BiologicsAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute LymphoblasticPhase 3NCT07152041
2029-12 (month only)PumitamigBioNTech, Bristol-Myers SquibbBreast NeoplasmsPhase 3NCT07173751
2029-12 (month only)Rondecabtagene autoleucelLyell Immunopharma, Inc.Large B-Cell LymphomaPhase 3NCT07188558
2029-12 (month only)AdebrelimabJiangsu Hengrui PharmaceuticalsAdvanced Biliary Tract CancerPhase 3NCT07229625
2029-12 (month only)AnakinraSwedish Orphan Biovitrum AB (publ)PEDIATRIC ACUTE MYOCARDITISPhase 3NCT07371689
2029-12 (month only)DocetaxelSanofiBladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urologic CancerPhase 3NCT07464145
2029-12 (month only)Tislelizumab, Izalontamab brengitecanBeOne Medicines, Bristol-Myers Squibb, Sichuan Baili PharmaceuticalSmall Cell Lung CancerPhase 3NCT07502300
2029-12 (month only)Pertuzumab, Trastuzumab brengitecanRoche, Sichuan Baili PharmaceuticalHER2-Positive Breast Cancer, Breast CancerPhase 3NCT07518173
2029-12 (month only)Adebrelimab, S-1Jiangsu Hengrui Pharmaceuticals, Nordic Group B.V., Taiho PharmaceuticalGastric CancerPhase 3NCT07522151
2029-12 (month only)Bevacizumab, Rinatabart sesutecan (Rina-S)Roche, GenmabOvarian CancerPhase 3NCT07564141
2029-12 (month only)LepodisiranDicerna Pharmaceuticals, Inc., Eli LillyAtherosclerotic Cardiovascular DiseasePhase 3NCT07613294
2029-12 (month only)Azacitidine, LisaftoclaxBristol-Myers Squibb, Ascentage Pharma Group Inc.Acute Myeloid LeukemiaPhase 2/3NCT07651163
2029-12 (month only)Azacitidine, LisaftoclaxBristol-Myers Squibb, Ascentage Pharma Group Inc.Acute Myeloid LeukemiaPhase 2/3NCT07651176
2029-12 (month only)SHR-1501Jiangsu Hengrui PharmaceuticalsNon-Muscle Invasive Bladder CancerPhase 3NCT07726992
2029-12 (month only)Izalontamab brengitecanBristol-Myers Squibb, Sichuan Baili PharmaceuticalTriple-Negative Breast Cancer (TNBC)Phase 3NCT07729956
2029-12 (month only)Izalontamab brengitecanBristol-Myers Squibb, Sichuan Baili PharmaceuticalNon-Small Cell Lung CancerPhase 2/3NCT07739186
2029-12 (month only)Izalontamab brengitecanBristol-Myers Squibb, Sichuan Baili PharmaceuticalNon-Small Cell Lung CancerPhase 2/3NCT07739199
2029-12 (month only)RC148AbbVie, RemeGen Co., Ltd.Non-Small Cell Lung CancerPhase 3NCT07756645
2029-12 (month only)Tirzepatide (Zepbound)Eli LillyObesityPhase 3NCT07817875
2029-12 (month only)Azacitidine, MesutoclaxBristol-Myers Squibb, Beijing InnoCare Pharma Tech Co.Acute Myeloid LeukemiaPhase 3NCT07925190
2029-12 (month only)QLS5132Qilu PharmaceuticalEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerPhase 3NCT07926048
2029-12-01RecaticimabJiangsu Hengrui PharmaceuticalsSymptomatic Intracranial Atherosclerotic StenosisPhase 3NCT07119918
2029-12-01Adebrelimab, CapecitabineJiangsu Hengrui Pharmaceuticals, Cheplapharm Arzneimittel GmbHNasopharyngeal Cancinoma (NPC), Nasopharangeal CancerPhase 3NCT07238569
2029-12-01faricimabChugai Pharma, RocheProliferative Sickle Cell RetinopathyPhase 3NCT07922460
2029-12-05Risvutatug rezetecanGlaxoSmithKline, Hansoh Pharmaceutical GroupNeoplasms, ProstatePhase 3NCT07802704
2029-12-07Calderasib, Pembrolizumab berahyaluronidase alfaMerck & Co.Non-Small Cell Lung CancerPhase 3NCT07190248
2029-12-07ElriterceptTakeda Pharmaceutical CompanyMyelofibrosis, AnemiaPhase 3NCT07623161
2029-12-13RevumenibSyndaxAcute Myeloid LeukemiaPhase 3NCT06652438
2029-12-13ObrixtamigBoehringer IngelheimExtrapulmonary Neuroendocrine Cancer (epNEC)Phase 3NCT07544654
2029-12-14VicadrostatBoehringer IngelheimType 2 Diabetes, HypertensionPhase 3NCT07064473
2029-12-14TicagrelorAstraZenecaSubarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular ProcedurePhase 3NCT07821008
2029-12-14QLS4131Qilu PharmaceuticalMultiple MyelomaPhase 3NCT07933432
2029-12-15CenvacibartRegeneron PharmaceuticalsSecondary StrokePhase 3NCT07876492
2029-12-17Dapagliflozin, BaxdrostatAstraZeneca, Ono Pharmaceutical, RocheHeart FailurePhase 3NCT06677060
2029-12-18Saruparib, Abemaciclib, Ribociclib, Camizestrant, Anastrozole, Fulvestrant, Palbociclib, Letrozole, ExemestaneAstraZeneca, Eli Lilly, NovartisHR+/HER2- Metastatic Breast Cancer, Breast CancerPhase 3NCT06380751
2029-12-18Dapagliflozin, BaxdrostatAstraZeneca, Ono Pharmaceutical, RocheChronic Kidney Disease, HypertensionPhase 3NCT06742723
2029-12-18zasocitinibTakeda Pharmaceutical CompanyPsoriatic ArthritisPhase 3NCT07286058
2029-12-18Xanomeline/trospium chlorideBristol-Myers Squibb, Zai LabSchizophreniaPhase 3NCT07288567
2029-12-19remibrutinibNovartisChronic Pruritus of Unknown OriginPhase 3NCT07700056
2029-12-26faricimabChugai Pharma, RocheRadiation Retinopathy, Visual ImpairmentPhase 3NCT05844982
2029-12-27BenralizumabAstraZeneca, Kyowa Kirin, MedImmune LLCAsthmaPhase 3NCT07444567
2029-12-28Datopotamab Deruxtecan, RilvegostomigAstraZeneca, Daiichi Sankyo, COMPUGEN LTDNon-Small Cell Lung CancerPhase 3NCT06357533
2029-12-28PovetaciceptVertex PharmaceuticalsIgA NephropathyPhase 3NCT07807995
2029-12-30CPO301, EnlonstobartConjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd.Esophageal Squamous Cell CarcinomaPhase 2/3NCT07251062
2029-12-30BevacizumabRocheOvarian CancerPhase 3NCT07821606
2029-12-30CPO301, EnlonstobartConjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Hangzhou Sumgen Biotech Co., Ltd.Esophageal Squamous Cell CarcinomaPhase 3NCT07924111
2029-12-31Daratumumab, Lenalidomide, DexamethasoneJohnson & Johnson, Bristol-Myers Squibb, Celgene CorporationMultiple MyelomaPhase 3NCT03937635
2029-12-31Semaglutide (Ozempic), FinerenoneNovo Nordisk, BayerChronic Kidney DiseasePhase 3NCT06058585
2029-12-31Temozolomide, DinutuximabMerck & Co., United TherapeuticsNeuroblastomaPhase 3NCT06172296
2029-12-31Ruxolitinib (Jakafi)Incyte, NovartisHematologic Malignancy, Solid Tumor, Advanced MalignanciesPhase 3NCT06401356
2029-12-31OcrelizumabRocheMultiple SclerosisPhase 3NCT06675955
2029-12-31Venetoclax, BlinatumomabAbbVie, Roche, AmgenAcute Lymphoblastic LeukemiaPhase 2/3NCT06764238
2029-12-31BlinatumomabAmgenAcute Lymphoblastic LeukemiaPhase 2/3NCT06882057
2029-12-31Nab-paclitaxelBristol-Myers SquibbLocally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic AdenocarcinomaPhase 3NCT06998940
2029-12-31picankibartInnovent BiologicsPsoriatic ArthritisPhase 2/3NCT07295509
2029-12-31TinengotinibTransThera Sciences (Nanjing), Inc.CholangiocarcinomaPhase 3NCT07328919
2029-12-31ToripalimabCoherus BioSciences, Inc., Shanghai Junshi BioscienceRectal CancerPhase 2/3NCT07505472
2029-12-31FinerenoneBayerHeart FailurePhase 3NCT07575672
2029-12-31PramipexoleBoehringer IngelheimBipolar Disorder (BD)Phase 3NCT07664852
2029-12-31Serplulimab, CapecitabineAbbott, Accord Healthcare, EisaiLocally Advanced Colon Cancer, pMMRPhase 3NCT07877597

Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.